Nicholas Investment Partners’s United Therapeutics UTHR Stock Holding History

Nicholas Investment Partners’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.87M	Buy	7,141 +45	+0.6%	+$25.3K	0.22%	139
2026 Q1	$4.21M	Buy	7,096 +2,543	+56%	+$1.27M	0.3%	112
2025 Q4	$2.22M	Buy	4,553 +3,766	+479%	+$1.75M	0.16%	150
2025 Q3	$330K	Buy	+787	New	+$265K	0.03%	205
2023 Q2	–	Sell	-119,506	Closed	-$26.8M	–	211
2023 Q1	$26.8M	Buy	+119,506	New	+$29.5M	2.03%	13
2022 Q4	–	Sell	-68,190	Closed	-$14.3M	–	199
2022 Q3	$14.3M	Buy	+68,190	New	+$15.2M	1.32%	21

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Nicholas Investment Partners's UTHR Position: Q2 2026 in Review

Nicholas Investment Partners increased its United Therapeutics (UTHR) stake by 0.63% in Q2 2026, buying an estimated $25.3K and bringing the position to 7,141 shares worth $3.87M. The position accounts for 0.22% of the portfolio, ranked #139.

Nicholas Investment Partners first reported a position in UTHR in Q3 2022 and has held it in 6 quarters since. The position peaked at $26.8M in Q1 2023. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Nicholas Investment Partners held 7,141 shares of United Therapeutics worth $3.87M as of Q2 2026.
Nicholas Investment Partners bought 45 United Therapeutics shares in Q2 2026, an estimated $25.3K.
United Therapeutics made up 0.22% of Nicholas Investment Partners's portfolio in Q2 2026, its #139 holding.
Nicholas Investment Partners first reported a position in United Therapeutics in Q3 2022 and has held it in 6 quarters since.
Nicholas Investment Partners's United Therapeutics position peaked at $26.8M in Q1 2023.
884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Nicholas Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.